Repligen (RGEN) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
634.4M
Gross Profit
274.6M
43.29%
Operating Income
-31.9M
-5.03%
Net Income
-25.5M
-4.02%
EPS (Diluted)
-$0.46
Balance Sheet Metrics
Total Assets
2.8B
Total Liabilities
856.9M
Shareholders Equity
2.0B
Debt to Equity
0.43
Cash Flow Metrics
Operating Cash Flow
164.1M
Free Cash Flow
142.5M
Revenue & Profitability Trend
Repligen Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 634.4M | 632.4M | 801.5M | 670.5M | 366.3M |
| Cost of Goods Sold | 359.8M | 353.9M | 345.8M | 279.3M | 156.6M |
| Gross Profit | 274.6M | 278.4M | 455.7M | 391.3M | 209.6M |
| Operating Expenses | 306.6M | 261.3M | 259.8M | 218.1M | 139.8M |
| Operating Income | -31.9M | 17.1M | 195.9M | 173.1M | 69.8M |
| Pre-tax Income | -27.0M | 56.7M | 219.1M | 153.5M | 59.2M |
| Income Tax | -1.5M | 21.1M | 33.2M | 25.3M | -709.0K |
| Net Income | -25.5M | 35.6M | 186.0M | 128.3M | 59.9M |
| EPS (Diluted) | -$0.46 | $0.63 | $3.24 | $2.24 | $1.11 |
Income Statement Trend
Repligen Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.1B | 1.1B | 998.1M | 931.7M | 902.4M |
| Non-Current Assets | 1.8B | 1.7B | 1.5B | 1.4B | 1.0B |
| Total Assets | 2.8B | 2.8B | 2.5B | 2.4B | 1.9B |
| Liabilities | |||||
| Current Liabilities | 126.8M | 164.9M | 404.2M | 375.3M | 319.0M |
| Non-Current Liabilities | 730.2M | 701.4M | 216.7M | 233.0M | 54.8M |
| Total Liabilities | 856.9M | 866.3M | 620.9M | 608.3M | 373.7M |
| Equity | |||||
| Total Shareholders Equity | 2.0B | 2.0B | 1.9B | 1.8B | 1.5B |
Balance Sheet Composition
Repligen Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -25.5M | 35.6M | 186.0M | 128.3M | 59.9M |
| Operating Cash Flow | 164.1M | 136.1M | 171.7M | 106.0M | 70.9M |
| Investing Activities | |||||
| Capital Expenditures | -25.7M | -36.2M | -84.8M | -67.1M | -22.5M |
| Investing Cash Flow | -79.2M | -120.5M | -184.7M | -217.0M | -197.5M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -87.2M | 247.9M | -17.1M | -3.0M | 297.8M |
| Free Cash Flow | 142.5M | 74.9M | 38.7M | 47.7M | 36.3M |
Cash Flow Trend
Repligen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
511.11
Forward P/E
69.30
Price to Book
3.49
Price to Sales
10.65
PEG Ratio
69.30
Profitability Ratios
Profit Margin
-3.53%
Operating Margin
5.59%
Return on Equity
-1.16%
Return on Assets
0.92%
Financial Health
Current Ratio
6.79
Debt to Equity
34.44
Beta
1.11
Per Share Data
EPS (TTM)
-$0.42
Book Value per Share
$35.34
Revenue per Share
$11.61
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| rgen | 6.9B | 511.11 | 3.49 | -1.16% | -3.53% | 34.44 |
| Intuitive Surgical | 189.7B | 77.39 | 11.09 | 15.96% | 28.41% | 0.00 |
| Becton, Dickinson | 50.0B | 33.87 | 1.98 | 5.89% | 7.18% | 76.34 |
| Avantor | 9.2B | 13.05 | 1.52 | 12.52% | 10.70% | 67.34 |
| Stevanato | 6.4B | 44.23 | 4.52 | 9.14% | 11.16% | 27.86 |
| Merit Medical | 5.5B | 45.25 | 3.82 | 9.16% | 8.81% | 57.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.